
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+20
Leaders of the Global Liquid Biopsy Revolution As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD). Plasma-Safe-SeQs NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as...
Mutation detection,sequence analysis,oncology,molecular diagnostics,circulating tumor dna,ctdna,plasma ngs,next generation sequencing ,digital pcr ,beaming,clinical trials ,ngs,clia,gcp,cancer,molecular testing,medicine,research,ivd kit ,plasma-safe-seqs,liquid biopsy,cfdna,cell free dna,cfhpv-dna,and lbx
Sysmex inostics operates in the Biotechnology research industry.
Sysmex inostics's revenue is 11m - 100m
Sysmex inostics has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.